mTOR-inhibiting medicine fact sheet
Sirolimus
Also known as rapamycin, Rapamune
Sirolimus is a powerful mTOR inhibitor with established medical uses. Early aging studies do not show that it extends human life or delivers a favorable risk-benefit balance for healthy people.
Quick answer
Sirolimus is FDA approved for specific transplant and lymphangioleiomyomatosis uses—not to slow aging or extend life. Small healthy-aging trials are exploratory, while approved labeling documents major infection, malignancy, metabolic, lung, wound-healing, and interaction risks.
By the PeptideFactSheets Editorial Team. Claims are source-checked under our editorial policy; clinician review is identified only when a named reviewer is shown.
What is Sirolimus?
Sirolimus is a macrolide medicine that inhibits mTOR, a signaling pathway involved in growth, nutrient sensing, immunity, and cell maintenance.
Rapamycin extends lifespan in several animal models, but translating that finding to healthy humans requires outcomes trials and careful safety testing.
Why are people interested in it?
mTOR is a central geroscience target, making sirolimus one of the most discussed drug-repurposing candidates in longevity research.
The same immune and growth pathways that make it scientifically interesting also explain why benefits cannot be considered separately from risk.
Current regulatory status
FDA-approved sirolimus products have specific indications, including prevention of organ rejection in selected kidney-transplant patients and treatment of lymphangioleiomyomatosis. Aging and longevity are not approved indications.
What is it approved for?
- Specific transplant and lymphangioleiomyomatosis uses described in current FDA-approved labeling
What is it being studied for?
Evidence snapshot
Evidence is strong for labeled medical uses, where monitoring and risk management are part of care. Healthy-aging evidence consists of small feasibility and exploratory trials without proof of longer life or prevention of age-related disease.
Potential benefits being researched
- Small aging trials suggest that controlled research is feasible and have reported selected exploratory signals.
- The PEARL trial did not establish a general longevity benefit and its primary visceral-fat outcome was not significantly improved overall.
A mechanism, biomarker, or secondary endpoint is not proof of a meaningful clinical benefit.
Known or possible risks
- Approved labeling carries boxed warnings and describes increased susceptibility to infection and possible development of malignancies.
- Other important risks include high cholesterol and triglycerides, impaired wound healing, mouth inflammation, blood-cell changes, lung toxicity, kidney-related concerns, and extensive drug interactions.
- Risk in closely monitored transplant or rare-disease care cannot be assumed acceptable for a healthy person seeking longevity.
What we still do not know
- Whether sirolimus can extend healthy human lifespan
- Whether any aging-related benefit outweighs immune, metabolic, and other harms
- Which biomarkers are meaningful rather than merely responsive
- Long-term outcomes in healthy or near-healthy populations
Plain-English takeaway
Sirolimus is not a generic anti-aging supplement. It is a consequential prescription immunosuppressant whose longevity use remains unproven.
Research and reference links
Use these primary and authoritative sources to verify status and read beyond this summary. A study or registry entry does not by itself prove benefit.
- 1FDA prescribing information: Rapamune
Official indications, boxed warnings, contraindications, adverse reactions, and interactions.
- 2PEARL randomized trial of sirolimus in healthy aging
Exploratory controlled trial that did not prove longevity or broad healthspan benefit.
- 3Pilot sirolimus study in older adults
Small randomized study focused on feasibility and selected physiological outcomes.